A Phase I, open-label, multi-center exploratory safety and efficacy study with PSMA, SSTR2 and GRPR targeted radioligand therapy in metastatic neuroendocrine prostate cancer

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505655-43-00

Acronym

CAAA617H12101

Enrollment

Registered

2024-05-08

Start date

2024-07-29

Completion date

Unknown

Last updated

2025-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic neuroendocrine prostate cancer

None listed

Sex/Gender

Male

Age

18 Years to No maximum

France, Germany, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026